INTRODUCTION: Risk reduction strategies for transfusion-related acute lung injury (TRALI) include the preferential use of male donors to provide fresh frozen plasma (FFP). Implementing this measure based on FFP quarantine program is a very complex process. To improve FFP inventory management and the availability of FFP from male donors, the Mirasol Pathogen Reduction Technology(®) (PRT) system for FFP using riboflavin and UV light was adopted in our region in 2012. METHODS: The percentage of male/female FFP units issued and TRALI cases in patients receiving FFP in the period before implementing riboflavin and UV light (2010-2011) was compared with the period post implementation of riboflavin and UV light (2012-2013). RESULTS: In 2010 and 2011, there was one FFP transfusion-related TRALI case reported per year, when the proportion of male/female FFP distributed to the hospitals was 60/40. During 2012 and 2013, there have been no FFP transfusion-related TRALI cases, when the proportion of male/female FFP distributed to the hospitals was around 97/3. Mirasol PRT allows quick availability (24 h from collection) compared to quarantined FFP (≥3 months from collection). CONCLUSION: Thanks to its readiness, simplicity and feasibility, riboflavin- and UV light-treated FFP implementation can facilitate the preferential use of FFP from male donors as a TRALI prevention strategy.
INTRODUCTION: Risk reduction strategies for transfusion-related acute lung injury (TRALI) include the preferential use of male donors to provide fresh frozen plasma (FFP). Implementing this measure based on FFP quarantine program is a very complex process. To improve FFP inventory management and the availability of FFP from male donors, the Mirasol Pathogen Reduction Technology(®) (PRT) system for FFP using riboflavin and UV light was adopted in our region in 2012. METHODS: The percentage of male/female FFP units issued and TRALI cases in patients receiving FFP in the period before implementing riboflavin and UV light (2010-2011) was compared with the period post implementation of riboflavin and UV light (2012-2013). RESULTS: In 2010 and 2011, there was one FFP transfusion-related TRALI case reported per year, when the proportion of male/female FFP distributed to the hospitals was 60/40. During 2012 and 2013, there have been no FFP transfusion-related TRALI cases, when the proportion of male/female FFP distributed to the hospitals was around 97/3. Mirasol PRT allows quick availability (24 h from collection) compared to quarantined FFP (≥3 months from collection). CONCLUSION: Thanks to its readiness, simplicity and feasibility, riboflavin- and UV light-treated FFP implementation can facilitate the preferential use of FFP from male donors as a TRALI prevention strategy.
Authors: A Alvarez-Larrán; J Del Río; C Ramírez; C Albo; F Peña; A Campos; J Cid; J Muncunill; J-L Sastre; C Sanz; A Pereira Journal: Vox Sang Date: 2004-05 Impact factor: 2.144
Authors: Hiroshi Asano; Chih-Yuan Lee; Karen Fox-Talbot; Cheryl M Koh; Melek M Erdinc; Susanne Marschner; Shawn Keil; Raymond P Goodrich; William M Baldwin Journal: Transplantation Date: 2007-11-15 Impact factor: 4.939
Authors: Kathryn E Webert; Christine M Cserti; Judy Hannon; Yulia Lin; Katerina Pavenski; Jacob M Pendergrast; Morris A Blajchman Journal: Transfus Med Rev Date: 2008-01
Authors: Loren D Fast; Martha Nevola; Jennifer Tavares; Heather L Reddy; Ray P Goodrich; Susanne Marschner Journal: Transfusion Date: 2012-05-21 Impact factor: 3.157
Authors: Anna Ettinger; Meghan M Miklauz; Brianna K Hendrix; David J Bihm; Gabriela Maldonado-Codina; Raymond P Goodrich Journal: Transfus Apher Sci Date: 2011-11-23 Impact factor: 1.764
Authors: Julio del Río-Garma; Alberto Alvarez-Larrán; Clara Martínez; Josep Muncunill; Dolors Castellà; Javier de la Rubia; Concepción Zamora; Mercedes Corral; Aurora Viejo; Francisco Peña; Pilar Rodríguez-Vicente; Enric Contreras; Cristina Arbona; Consuelo Ramírez; José A Garcia-Erce; Adrián Alegre; José Mateo; Arturo Pereira Journal: Br J Haematol Date: 2008-07-14 Impact factor: 6.998